Evidence map›Paper›PMID 39572596›Full record

ArticleScientific reports2024

Multi-layered proteomics identifies insulin-induced upregulation of the EphA2 receptor via the ERK pathway which is dependent on low IGF1R level.

Sarah Hyllekvist Jørgensen, Kristina Bennet Emdal, Anna-Kathrine Pedersen, Lene Nygaard Axelsen, Helene Faustrup Kildegaard, Damien Demozay, Thomas Åskov Pedersen, Mads Grønborg, Rita Slaaby, Peter Kresten Nielsen and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah Hyllekvist JørgensenProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Kristina Bennet EmdalProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark. kristina.emdal@cpr.ku.dk.
Anna-Kathrine PedersenProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Lene Nygaard AxelsenGlobal Translation, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Helene Faustrup KildegaardGlobal Nucleic Acid Therapies, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Damien DemozayGlobal Drug Discovery, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Thomas Åskov PedersenGlobal Drug Discovery, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Mads GrønborgGlobal Translation, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Rita SlaabyGlobal Drug Discovery, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Peter Kresten NielsenGlobal Research Technologies, Novo Nordisk A/S, 2760, Maaloev, Denmark.
Jesper Velgaard OlsenProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark. jesper.olsen@cpr.ku.dk.

Funding

European Research Council 810057-HighResCellsInnovationsfonden 0153-00008Novo Nordisk Novo Nordisk STAR Fellowship ProgramNovo Nordisk Fonden NNF14CC0001
6 · The paper itself

Abstract

Insulin resistance impairs the cellular insulin response, and often precedes metabolic disorders, like type 2 diabetes, impacting an increasing number of people globally. Understanding the molecular mechanisms in hepatic insulin resistance is essential for early preventive treatments. To elucidate changes in insulin signal transduction associated with hepatocellular resistance, we employed a multi-layered mass spectrometry-based proteomics approach focused on insulin receptor (IR) signaling at the interactome, phosphoproteome, and proteome levels in a long-term hyperinsulinemia-induced insulin-resistant HepG2 cell line with a knockout of the insulin-like growth factor 1 receptor (IGF1R KO). The analysis revealed insulin-stimulated recruitment of the PI3K complex in both insulin-sensitive and -resistant cells. Phosphoproteomics showed attenuated signaling via the metabolic PI3K-AKT pathway but sustained extracellular signal-regulated kinase (ERK) activity in insulin-resistant cells. At the proteome level, the ephrin type-A receptor 2 (EphA2) showed an insulin-induced increase in expression, which occurred through the ERK signaling pathway and was concordantly independent of insulin resistance. Induction of EphA2 by insulin was confirmed in additional cell lines and observed uniquely in cells with high IR-to-IGF1R ratio. The multi-layered proteomics dataset provided insights into insulin signaling, serving as a resource to generate and test hypotheses, leading to an improved understanding of insulin resistance.

Indexed as

InsulinInsulin ResistanceMAP Kinase Signaling SystemProteomicsReceptor, EphA2Receptor, IGF Type 1Hep G2 CellsHumansPhosphatidylinositol 3-KinasesReceptor, InsulinSignal TransductionUp-RegulationEPHA2 protein, humanIGF1R protein, humanInsulinPhosphatidylinositol 3-KinasesReceptor, EphA2Receptor, IGF Type 1Receptor, Insulin

Identifiers

PMID39572596
PMCPMC11582730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.